ArticleAnalytical and bioanalytical chemistry2026
Infection metallomics of pulmonary mucormycosis: multi-omics study of siderophore secretion, neutrophil recruitment, and lipid remodeling in rat lungs.
Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Invasive pulmonary mucormycosis caused by Rhizopus microsporus is often fatal, yet analytical tools to monitor fungal burden and host responses in vivo remain limited. We developed a multimodal infection metallomics workflow combining ⁶⁸Ga-desferrioxamine B PET/CT, high-resolution MALDI mass spectrometry imaging (MALDI-MSI), and targeted LC-MS to map fungal siderophore production and host tissue remodeling in a neutropenic rat model and in human samples. ⁶⁸Ga-desferrioxamine B was rapidly taken up by R. microsporus in vitro and accumulated in infected lungs in vivo. MALDI-MSI visualized rhizoferrin (m/z 435.1259, [M-H]⁻) and homorhizoferrin (m/z 449.1420, [M-H]⁻) confined to hyphal foci and absent from control lungs, whereas heme b was depleted and spatially segregated. Neutrophil α-defensins (RatNP-2/3/4) increased 14-60-fold and formed halos around lesions, showing an inverse trend with siderophore abundance. Lipid MSI revealed remodeling of anionic surfactant lipids, with depletion of short-chain phosphatidylglycerols and phosphatidic acid-derived species and accumulation of long-chain polyunsaturated phosphatidylglycerols and phosphatidylinositols in infected regions. Targeted LC-MS of serial urine showed that rhizoferrin and homorhizoferrin emerged by day 2, peaked on day 4 (37.2 and 15.0 µg/mL), and declined with immune reconstitution; rhizoferrin was also detected in bronchoalveolar lavage from a patient with mucormycosis. Analytically, the workflow links radiotracer uptake, high-mass-accuracy spatial ion mapping of peptides with lipids, and matrix-matched urinary LC-MS quantitation within the same infection model. This integrated platform enables spatially resolved mechanistic readouts and supports non-invasive metallophore-based diagnostics of invasive mucormycosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.